Lodoxamide Tromethamine

Lodoxamide Tromethamine is antiallergic and used in the treatment of allergic conjunctivitis. Lodoxamide Tromethamine is a mast cell stabilizer with a similar profile of activity to Cromolyn Sodium. Lodoxamide Tromethamine is prepared by chemical synthesis and not present in any combination preparations. Lodoxamide Tromethamine is available for ophthalmic administration.

Lodoxamide Tromethamine is primarily indicated in conditions like Allergic perennial conjunctivitis, Atopic conjunctivitis, Keratosis, Vernal keratoconjunctivitis.

Lodoxamide Tromethamine is contraindicated in conditions like Hypersensitivity.

During clinical studies of ALOMIDE ® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adverse experiences were transient burning, stinging, or discomfort upon instillation, which occurred in approximately 15% of the subjects. Other ocular events occurring in 1% to 5% of the subjects included ocular itching/pruritus, blurred vision, dry eye, tearing/discharge, hyperemia, crystalline deposits, and foreign body sensation. Events that occurred in less than 1% of the subjects included corneal erosion/ulcer, scales on lid/lash, eye pain, ocular edema/swelling, ocular warming sensation, ocular fatigue, chemosis, corneal abrasion, anterior chamber cells, keratopathy/keratitis, blepharitis, allergy, sticky sensation, and epitheliopathy. Nonocular events reported were headache (1.5%) and (at less than 1%) heat sensation, dizziness, somnolence, nausea, stomach discomfort, sneezing, dry nose, and rash.

FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION. As with all ophthalmic preparations containing benzalkonium chloride, patients should be instructed not to wear soft contact lenses during treatment with ALOMIDE ® (lodoxamide tromethamine ophthalmic solution) 0.1%. Do not touch the dropper tip to any surface, as this may contaminate the solution.

FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION. As with all ophthalmic preparations containing benzalkonium chloride, patients should be instructed not to wear soft contact lenses during treatment with ALOMIDE ® (lodoxamide tromethamine ophthalmic solution) 0.1%. Do not touch the dropper tip to any surface, as this may contaminate the solution.

0.05 to 0.1 % (0.075 (0.075)) 6 hourly Ophthalmic — - Scraped Dose — There have been no reports of ALOMIDE ® (lodoxamide tromethamine ophthalmic solution) 0.1% overdose following topical ocular application. Accidental overdose of an oral preparation of 120 mg to 180 mg of lodoxamide resulted in a temporary sensation of warmth, profuse sweating, diarrhea, light-headedness, and a feeling of stomach distension; no permanent adverse effects were observed. Side effects reported following systemic oral administration of 0.1 mg to 10 mg of lodoxamide include a feeling of warmth or flushing, headache, dizziness, fatigue, sweating, nausea, loose stools, and urinary frequency/urgency. The physician may consider emesis in the event of accidental ingestion.

SA ( ) —

( ) — Not recommended in this age group

No data regarding the interactions of Lodoxamide Tromethamine was found.

Eye Drops Store Below 40°C. Do not Freeze. Protect from Sunlight and Heat.